Easy Access and Express Report Delivery Service
Table 155. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Biosimilar Product Picture
Figure 5. Global Biosimilar Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 6. Global Biosimilar Market Share by Type: 2022 VS 2029
Figure 7. Biosimilar Monoclonal Antibodies Product Picture
Figure 8. Biosimilar Insulin Product Picture
Figure 9. Others Product Picture
Figure 10. Global Biosimilar Market Size by Application (2023-2029) & (US$ Million)
Figure 11. Global Biosimilar Market Share by Application: 2022 VS 2029
Figure 12. Cancer Product Picture
Figure 13. Immunological Diseases Product Picture
Figure 14. Diabetes Product Picture
Figure 15. Others Product Picture
Figure 16. Global Biosimilar Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 17. Global Biosimilar Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 18. Global Biosimilar Market Share by Region: 2022 VS 2029
Figure 19. Global Biosimilar Market Share by Players in 2022
Figure 20. Global Biosimilar Players, Date of Enter into This Industry
Figure 21. Global Top 5 and 10 Biosimilar Players Market Share by Revenue in 2022
Figure 22. Players Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 23. North America Biosimilar Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. North America Biosimilar Market Share by Country (2018-2029)
Figure 25. United States Biosimilar Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Canada Biosimilar Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Europe Biosimilar Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Europe Biosimilar Market Share by Country (2018-2029)
Figure 29. Germany Biosimilar Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. France Biosimilar Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. U.K. Biosimilar Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Italy Biosimilar Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Russia Biosimilar Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Nordic Countries Biosimilar Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Asia-Pacific Biosimilar Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Asia-Pacific Biosimilar Market Share by Country (2018-2029)
Figure 37. China Biosimilar Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Japan Biosimilar Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. South Korea Biosimilar Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Southeast Asia Biosimilar Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. India Biosimilar Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Australia Biosimilar Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Latin America Biosimilar Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Latin America Biosimilar Market Share by Country (2018-2029)
Figure 45. Mexico Biosimilar Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Brazil Biosimilar Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Middle East & Africa Biosimilar Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Middle East & Africa Biosimilar Market Share by Country (2018-2029)
Figure 49. Turkey Biosimilar Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 50. Saudi Arabia Biosimilar Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 51. UAE Biosimilar Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 52. Qilu Pharmaceutical Revenue Growth Rate in Biosimilar Business (2018-2023)
Figure 53. Bio-Thera Revenue Growth Rate in Biosimilar Business (2018-2023)
Figure 54. Zhejiang Hisun Revenue Growth Rate in Biosimilar Business (2018-2023)
Figure 55. Shanghai Henlius Revenue Growth Rate in Biosimilar Business (2018-2023)
Figure 56. Innovent Biologics Revenue Growth Rate in Biosimilar Business (2018-2023)
Figure 57. Jiangsu Hengrui Revenue Growth Rate in Biosimilar Business (2018-2023)
Figure 58. Gan&Lee Revenue Growth Rate in Biosimilar Business (2018-2023)
Figure 59. Tonghua Dongbao Revenue Growth Rate in Biosimilar Business (2018-2023)
Figure 60. United Laboratory Revenue Growth Rate in Biosimilar Business (2018-2023)
Figure 61. 3SBIO Revenue Growth Rate in Biosimilar Business (2018-2023)
Figure 62. Luye Pharma Revenue Growth Rate in Biosimilar Business (2018-2023)
Highlights
The global Biosimilar market is projected to reach US$ million by 2029 from an estimated US$ million in 2023, at a CAGR of % during 2024 and 2029.
North American market for Biosimilar is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2024 through 2029.
Asia-Pacific market for Biosimilar is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2024 through 2029.
The major global companies of Biosimilar include Qilu Pharmaceutical, Bio-Thera, Zhejiang Hisun, Shanghai Henlius, Innovent Biologics, Jiangsu Hengrui, Gan&Lee, Tonghua Dongbao and United Laboratory, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
The global market for Biosimilar in Cancer is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2024 through 2029.
Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, Biosimilar Monoclonal Antibodies, which accounted for % of the global market of Biosimilar in 2022, is expected to reach million US$ by 2029, growing at a revised CAGR of % from 2024 to 2029.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Biosimilar, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar.
The Biosimilar market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Biosimilar market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilar companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
Qilu Pharmaceutical
Bio-Thera
Zhejiang Hisun
Shanghai Henlius
Innovent Biologics
Jiangsu Hengrui
Gan&Lee
Tonghua Dongbao
United Laboratory
3SBIO
Luye Pharma
Product Type Insights
Global markets are presented by Biosimilar type, along with growth forecasts through 2029. Estimates on revenue are based on the price in the supply chain at which the Biosimilar are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).
Biosimilar segment by Type
Biosimilar Monoclonal Antibodies
Biosimilar Insulin
Others
Application Insights
This report has provided the market size (revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).
This report also outlines the market trends of each segment and consumer behaviors impacting the Biosimilar market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Biosimilar market.
Biosimilar Segment by Application
Cancer
Immunological Diseases
Diabetes
Others
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2018-2029.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2022 because of the base year, with estimates for 2023 and forecast revenue for 2029.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Biosimilar market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Biosimilar industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Biosimilar companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
Frequently Asked Questions
What factors will challenge the Product Name market growth?
Which end-use segment will expand at the fastest CAGR in the Product Name market?
Which are the emerging players in the Product Name market?
How concentrated is the Product Name market?
Which factors are positively contributing to the Product Name market growth?
Which are the novel product innovations in the Product Name market?
Which product segment will emerge as the most lucrative in the Product Name market?
Which factors are increasing the competition in the Product Name market?
Which are the strategic measures taken by the Product Name industry players?
Which region will witness inactive growth during the forecast period?
What key trends are likely to emerge in the Product Name market in the coming years?
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Biosimilar by Type
2.2.1 Market Value Comparison by Type (2018 VS 2022 VS 2029)
1.2.2 Biosimilar Monoclonal Antibodies
1.2.3 Biosimilar Insulin
1.2.4 Others
2.3 Biosimilar by Application
2.3.1 Market Value Comparison by Application (2018 VS 2022 VS 2029)
2.3.2 Cancer
2.3.3 Immunological Diseases
2.3.4 Diabetes
2.3.5 Others
2.4 Assumptions and Limitations
3 Biosimilar Breakdown Data by Type
3.1 Global Biosimilar Historic Market Size by Type (2018-2023)
3.2 Global Biosimilar Forecasted Market Size by Type (2023-2028)
4 Biosimilar Breakdown Data by Application
4.1 Global Biosimilar Historic Market Size by Application (2018-2023)
4.2 Global Biosimilar Forecasted Market Size by Application (2018-2023)
5 Global Growth Trends
5.1 Global Biosimilar Market Perspective (2018-2029)
5.2 Global Biosimilar Growth Trends by Region
5.2.1 Global Biosimilar Market Size by Region: 2018 VS 2022 VS 2029
5.2.2 Biosimilar Historic Market Size by Region (2018-2023)
5.2.3 Biosimilar Forecasted Market Size by Region (2024-2029)
5.3 Biosimilar Market Dynamics
5.3.1 Biosimilar Industry Trends
5.3.2 Biosimilar Market Drivers
5.3.3 Biosimilar Market Challenges
5.3.4 Biosimilar Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Biosimilar Players by Revenue
6.1.1 Global Top Biosimilar Players by Revenue (2018-2023)
6.1.2 Global Biosimilar Revenue Market Share by Players (2018-2023)
6.2 Global Biosimilar Industry Players Ranking, 2021 VS 2022 VS 2023
6.3 Global Key Players of Biosimilar Head office and Area Served
6.4 Global Biosimilar Players, Product Type & Application
6.5 Global Biosimilar Players, Date of Enter into This Industry
6.6 Global Biosimilar Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Biosimilar Market Size (2018-2029)
7.2 North America Biosimilar Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 North America Biosimilar Market Size by Country (2018-2023)
7.4 North America Biosimilar Market Size by Country (2024-2029)
7.5 United States
7.6 Canada
8 Europe
8.1 Europe Biosimilar Market Size (2018-2029)
8.2 Europe Biosimilar Market Growth Rate by Country: 2018 VS 2022 VS 2029
8.3 Europe Biosimilar Market Size by Country (2018-2023)
8.4 Europe Biosimilar Market Size by Country (2024-2029)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Biosimilar Market Size (2018-2029)
9.2 Asia-Pacific Biosimilar Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Asia-Pacific Biosimilar Market Size by Country (2018-2023)
9.4 Asia-Pacific Biosimilar Market Size by Country (2024-2029)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
10 Latin America
10.1 Latin America Biosimilar Market Size (2018-2029)
10.2 Latin America Biosimilar Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Latin America Biosimilar Market Size by Country (2018-2023)
10.4 Latin America Biosimilar Market Size by Country (2024-2029)
9.4 Mexico
9.5 Brazil
11 Middle East & Africa
11.1 Middle East & Africa Biosimilar Market Size (2018-2029)
11.2 Middle East & Africa Biosimilar Market Growth Rate by Country: 2018 VS 2022 VS 2029
11.3 Middle East & Africa Biosimilar Market Size by Country (2018-2023)
11.4 Middle East & Africa Biosimilar Market Size by Country (2024-2029)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
12 Players Profiled
11.1 Qilu Pharmaceutical
11.1.1 Qilu Pharmaceutical Company Detail
11.1.2 Qilu Pharmaceutical Business Overview
11.1.3 Qilu Pharmaceutical Biosimilar Introduction
11.1.4 Qilu Pharmaceutical Revenue in Biosimilar Business (2017-2022)
11.1.5 Qilu Pharmaceutical Recent Development
11.2 Bio-Thera
11.2.1 Bio-Thera Company Detail
11.2.2 Bio-Thera Business Overview
11.2.3 Bio-Thera Biosimilar Introduction
11.2.4 Bio-Thera Revenue in Biosimilar Business (2017-2022)
11.2.5 Bio-Thera Recent Development
11.3 Zhejiang Hisun
11.3.1 Zhejiang Hisun Company Detail
11.3.2 Zhejiang Hisun Business Overview
11.3.3 Zhejiang Hisun Biosimilar Introduction
11.3.4 Zhejiang Hisun Revenue in Biosimilar Business (2017-2022)
11.3.5 Zhejiang Hisun Recent Development
11.4 Shanghai Henlius
11.4.1 Shanghai Henlius Company Detail
11.4.2 Shanghai Henlius Business Overview
11.4.3 Shanghai Henlius Biosimilar Introduction
11.4.4 Shanghai Henlius Revenue in Biosimilar Business (2017-2022)
11.4.5 Shanghai Henlius Recent Development
11.5 Innovent Biologics
11.5.1 Innovent Biologics Company Detail
11.5.2 Innovent Biologics Business Overview
11.5.3 Innovent Biologics Biosimilar Introduction
11.5.4 Innovent Biologics Revenue in Biosimilar Business (2017-2022)
11.5.5 Innovent Biologics Recent Development
11.6 Jiangsu Hengrui
11.6.1 Jiangsu Hengrui Company Detail
11.6.2 Jiangsu Hengrui Business Overview
11.6.3 Jiangsu Hengrui Biosimilar Introduction
11.6.4 Jiangsu Hengrui Revenue in Biosimilar Business (2017-2022)
11.6.5 Jiangsu Hengrui Recent Development
11.7 Gan&Lee
11.7.1 Gan&Lee Company Detail
11.7.2 Gan&Lee Business Overview
11.7.3 Gan&Lee Biosimilar Introduction
11.7.4 Gan&Lee Revenue in Biosimilar Business (2017-2022)
11.7.5 Gan&Lee Recent Development
11.8 Tonghua Dongbao
11.8.1 Tonghua Dongbao Company Detail
11.8.2 Tonghua Dongbao Business Overview
11.8.3 Tonghua Dongbao Biosimilar Introduction
11.8.4 Tonghua Dongbao Revenue in Biosimilar Business (2017-2022)
11.8.5 Tonghua Dongbao Recent Development
11.9 United Laboratory
11.9.1 United Laboratory Company Detail
11.9.2 United Laboratory Business Overview
11.9.3 United Laboratory Biosimilar Introduction
11.9.4 United Laboratory Revenue in Biosimilar Business (2017-2022)
11.9.5 United Laboratory Recent Development
11.10 3SBIO
11.10.1 3SBIO Company Detail
11.10.2 3SBIO Business Overview
11.10.3 3SBIO Biosimilar Introduction
11.10.4 3SBIO Revenue in Biosimilar Business (2017-2022)
11.10.5 3SBIO Recent Development
11.11 Luye Pharma
11.11.1 Luye Pharma Company Detail
11.11.2 Luye Pharma Business Overview
11.11.3 Luye Pharma Biosimilar Introduction
11.11.4 Luye Pharma Revenue in Biosimilar Business (2017-2022)
11.11.5 Luye Pharma Recent Development
13 Report Conclusion
14 Disclaimer